APR 19, 2017 8:02 PM PDT

Resilient T Cells Provide Cancer Treatment and Immunity

WRITTEN BY: Kara Marker

A key part of the process to create immunotherapies for the treatment of cancer involves rapid expansion protocols (REPs) and immune cells extracted from hosts. The idea is to put the immune cells back once they have been altered to be bigger and better at killing cancer, but previous targets, namely CD8+ T cells, lose their power after going through REPs. However, scientists have now identified a better target cell that could completely change immunotherapy approaches.

FierceBiotech

CD8+ T cells might not be cut out for long-term REPs, a necessary step in adoptive cancer immunotherapy (ACT). Th17 cells, though, appear to be uniquely eligible for the task; as compared to CD8+ T cells that show reduced efficacy after going through REPs, Th17 cells are more resilient and durable throughout the expansion process.

As an immunotherapy approach, ACT revolves around “The Three Es:” extracting, expanding, and enhancing host T cells for eventual return to the body to fight cancer. REPs are necessary but tough on T cells, and it can take up months to adequately prepare cells. After several weeks of preparation, CD8+ T cells often lose their power, but Th17 cells have been shown to be “resistant to expansion-induced degradation,” making them an obvious replacement for the seemingly “delicate” CD8+ cells.

"Th17 cells have a natural propensity to logarithmically expand without restimulation,” explained research leader Chrystal Paulos, PhD. “And, if we did restimulate them, this approach didn't dramatically impair the antitumor response as with CD8+ T cells."

What makes Th17 cells special? Stem cell-like properties. Paulos’s study showed that Th17 cells produced five thousand times the original number of cells when expanded for three weeks outside of the body thanks to their “natural propensity.”

Credit: Dr. Chrystal Paulos and Jacob Bower

In addition to retaining stem memory, resisting degradation, and effectively targeting melanoma in a mice model, after extraction and two weeks of expansion Th17 cells also remained in the tumor-bearing host after being returned to the body, indicating a protective effect for any possible recurrences of the cancer.

“When we rechallenged the same animals with another lethal tumor dose, these mice were protected but the control mice died quickly,” Paulos said. “Then we came back again 100 days later and gave these mice lung tumors and they were all still protected many months later."

Even more promising, the “remarkably potent antitumor response” seems to be extendable to the treatment of other cancer types, with an anti-cancer immunity effect “superior” to that obtained by classic applications of immunotherapy.

Sources: Medical University of South Carolina, JCI Insight

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 11, 2020
Immunology
Could a Drug for Cats Treat COVID?
SEP 11, 2020
Could a Drug for Cats Treat COVID?
Canadian researchers have discovered that a drug used to treat coronavirus infections in cats shows promise in helping C ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 12, 2020
Genetics & Genomics
The Malaria Parasite Can Change Host Cell Genetics
OCT 12, 2020
The Malaria Parasite Can Change Host Cell Genetics
Mosquitoes can transmit the malaria-causing Plasmodium parasite to humans. Malaria was estimated to have caused the deat ...
NOV 01, 2020
Cell & Molecular Biology
There's More to Neutrophil Function Than We Knew
NOV 01, 2020
There's More to Neutrophil Function Than We Knew
Neutrophils are an abundant type of white blood cell that circulate in the blood that can provide a general defense aga ...
NOV 04, 2020
Coronavirus
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
NOV 04, 2020
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
COVID-19, the illness caused by the pandemic virus SARS-CoV-2, is known to cause blood clots all over the body in some p ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
Loading Comments...